FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasinigton,	D.C.	20040

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) C/O TEN	Whitten (F NAYA THE	irst) RAPEUTICS, IN		<u>]</u>	S. Issuer Name and Ticker or Trading Symbol Tenaya Therapeutics, Inc. [TNYA] S. Date of Earliest Transaction (Month/Day/Year) 02/15/2022					(Ch	below) `		ner necify				
(Street) SOUTH FRANCI (City)	SAN ISCO C	T BLVD., 5TH	94080 (Zip)	4	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	ndividual or Joint/Group Filing (Check Applicable) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Та	ble I - Non-D	erivati	ive S	ecuritie	s Ac	quired	, Dis	posed o	f, or Bei	neficiall	y Owned				
Date				Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 8) Disposed Of (D) (Instr. 3, 4)		tr. 3, 4 and	Securities Beneficial Owned Fo Reported Transactio	Securities Form Beneficially (D) (O) (I) (II)		rect In direct B 4) O	Nature of idirect eneficial wnership nstr. 4)						
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
		Transa Code (saction Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Seci (Instr. 3 and 4)		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	y Di or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
				Code	v	(A)	(D)	Date Exercisal	ole	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	11(5)		
Stock Option (Right to buy)	\$15.19	02/15/2022		A		141,000		03/15/202	2(1)	02/14/2032	Common Stock	141,000	\$0.00	141,000)	D	

Explanation of Responses:

1. Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one (1) month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

Remarks:

/s/ Jennifer Drimmer Rokovich,

** Signature of Reporting Person

02/17/2022

Attorney-in-Fact

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned, as a Section 16 reporting person of Tenaya Therapeutics, Inc. (the Company), hereby constitutes and appoints Faraz Ali, Leone Patterson and Jennifer Drimmer Rokovich, and each of them, as the true and lawful attorney-in-fact of the undersigned to:

- 1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the ownership, acquisition or disposition of securities of the Company by the undersigned; and
- 2. do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the responsibilities of the undersigned to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 14 day of February, 2022.

Signature: /s/ Whit Tingley

Print Name: Whit Tingley